An Open Label Study of Bavituximab and Pembrolizumab in Advanced Gastric and GEJ Cancer Patients

A Phase 2, Multicenter Open-label, Non-randomized Study of Bavituximab Plus Pembrolizumab in Patients With Advanced Gastric or Gastroesophageal Cancer Who Have Progressed on or After at Least One Prior Standard Therapy

This study evaluates the combination of bavituximab and pembrolizumab in the treatment of gastric and gastroesphogeal cancer. All patients will receive both bavituximab, a drug that is not yet approved by the FDA, and pembrolizumab known as Keytruda.

There is no expanded access program available for the investigational agents per this protocol.

Study Overview

• Status: Completed
• Conditions: Gastric Cancer; GastroEsophageal Cancer
• Intervention / Treatment: Drug: Bavituximab; Drug: Pembrolizumab Injection

• Study Type: Interventional
• Enrollment (Actual): 80
• Phase: Phase 2

Contacts and Locations

Study Locations

• Korea, Republic of
  • Busan, Korea, Republic of, 49201
    • Dong-A University Hospital
  • Daegu, Korea, Republic of, 702-210
    • Kyungpook National University Chilgok Hospital
  • Seongnam-si, Korea, Republic of, 13620
    • Seoul National University Bundang Hospital
  • Seoul, Korea, Republic of, 110-744
    • Seoul National University Hospital
  • Seoul, Korea, Republic of, 05505
    • Asan Medical Center
  • Seoul, Korea, Republic of, 06351
    • Samsung Medical Center
• Taiwan
  • Taichung, Taiwan, 40447
    • China Medical University Hospital
  • Tainan, Taiwan, 704
    • National Cheng Kung University Hospital
  • Taipei, Taiwan, 11217
    • Taipei Veterans General Hospital
  • Taoyuan, Taiwan, 33305
    • Chang Gung Medical Foundation - Linkou Branch
• United Kingdom
  • London, United Kingdom, W1G 6AD
    • Sarah Cannon Research Institute
  • London, United Kingdom, SW3 6JJ
    • The Royal Marsden
• United States
  • Connecticut
    • New Haven, Connecticut, United States, 06511
      • Smilow Cancer Hospital at Yale-New Haven
  • Florida
    • Weston, Florida, United States, 33331
      • Cleveland Clinic Florida - Weston
  • Georgia
    • Columbus, Georgia, United States, 31904
      • Columbus Regional Research Institute
  • Illinois
    • Chicago, Illinois, United States, 60637
      • The University of Chicago Medical Center
  • Missouri
    • Saint Louis, Missouri, United States, 63110
      • Siteman Cancer Center - Washington University Medical Campus
  • New York
    • White Plains, New York, United States, 10601
      • White Plains Hospital - Center for Cancer Care
  • Ohio
    • Cincinnati, Ohio, United States, 45229
      • UC Health Office of Clinical Research
  • Pennsylvania
    • Philadelphia, Pennsylvania, United States, 19124
      • Cancer Treatment Centers of America at Eastern Regional Medical Center
  • Tennessee
    • Nashville, Tennessee, United States, 37203
      • Sara Cannon Research Institute

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Signed written informed consent
• Men and women ≥ 18 years old; ≥ 20 years old in South Korea and Taiwan
• Unresectable metastatic or locally advanced gastric or GEJ adenocarcinoma
• Progressed on and/or after at least 1 prior regimen for metastatic disease or achieved stable disease or better in two consecutive scans to PD-1/PD-L1 inhibition alone or in combination with chemotherapy and relapsed
• Willing and able to provide fresh formalin-fixed paraffin-embedded tissue tumor sample
• Presence of at least one measurable lesion
• ECOG of 0 or 1
• Has adequate organ functions
• Women of childbearing potential must have a negative serum or urine pregnancy test within 72 hours prior to start of study treatment.
• Women must not be breastfeeding.
• Women of childbearing potential , must agree to follow instructions for highly effective method(s) of contraception
• Males who are sexually active with women of childbearing potential must agree to follow instructions for highly effective method(s) of contraception
• Has adequate treatment washout period before start of study treatment

Exclusion Criteria:

• Received any form of anti-phosphatidylserine therapies
• Prior treatment with any checkpoint inhibitor or other therapies targeting T-cell control
• Known microsatellite instability-high (MSI-H) gastric or GEJ adenocarcinoma
• Medical history of myocardial infarction within 6 months before registration, symptomatic congestive heart failure (CHF) , troponin levels consistent with myocardial infarction, unstable angina, or serious cardiac arrhythmia
• Weight loss >10% over 2 months prior to first dose of study treatment
• History of pneumonitis that required steroids or has current pneumonitis
• Has known active CNS metastases/and or carcinomatous meningitis
• Known additional malignancy that is progressing or has required active treatment in within the past 3 years
• An active infection requiring systemic therapy
• Known human immunodeficiency virus (HIV) infection or known acute hepatitis B or C infection
• Unresolved toxicities from previous cancer treatments
• History or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the participant's participation for the full duration of the study, or is not in the best interest of the participant to participate, in the opinion of the treating investigator
• Active autoimmune disease or history of chronic recurrent autoimmune disease
• Severe hypersensitivity (≥ Grade 3) to pembrolizumab and/or any of its excipients.
• History of infusion reactions to any component/excipient of bavituximab
• History of severe hypersensitivity reactions to mAbs.
• Systemic steroid therapy within 7 days prior to the first dose of study treatment
• Has received a live vaccine within 30 days prior to first dose of study drug.
• Prior organ transplantation including allogeneic or autologous stem-cell transplantation
• Currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study treatment
• Receipt of treatment with immunotherapy, biological therapies, or therapeutic doses of hormonal therapies within 3 weeks of scheduled C1D1 dosing
• Known psychiatric, substance abuse disorder, or geographical travel limitations that would interfere with participant's ability to cooperate with the requirements of the study
• Pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the study

Study Plan

How is the study designed?

Design Details

• Primary Purpose: TREATMENT
• Allocation: NA
• Interventional Model: SINGLE_GROUP
• Masking: NONE

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
EXPERIMENTAL: bavituximab and pembrolizumab; Bavituximab 3mg/kg IV weekly in combination with pembrolizumab 200mg IV given once every 3 weeks	Drug: Bavituximab; Bavituximab IV infusion; Drug: Pembrolizumab Injection; Pembrolizumab IV Infusion; Other Names: Keytruda

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of Patients With Treatment Emergent Adverse Events (TEAE)	Incidence of TEAEs graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v5.0, including changes in clinical laboratory parameters. TEAEs: any AE that emerged on or after first dose, and within 30 days of the last dose.	From first dose through 30 days after last dose. Maximum exposure: 567 days.
Severity of Treatment Emergent Adverse Events (TEAE)	Severity of TEAEs graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v5.0, including changes in clinical laboratory parameters. TEAEs: any AE that emerged on or after first dose, and within 30 days of the last dose.	From first dose through 30 days after last dose. Maximum exposure: 567 days.
Objective Response Rate (ORR)	ORR was based on RECIST version 1.1 criteria for target lesions, where a patient may achieve as best overall response (BOR) either complete response (CR), partial response (PR), stable disease (SD), or progressive disease (PD). CR was defined as the disappearance of all target lesions. PR was defined as at least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline summary of diameters. ORR is calculated as the number of patients achieving a CR or PR (objective response) divided by the number of efficacy patients.	From date of first dose until the date of CR, PR, first documented progression or date of death from any cause, whichever came first. Maximum exposure: 567 days.

Collaborators and Investigators

• Sponsor: OncXerna Theraputics, Inc.
• Collaborators: Merck Sharp & Dohme LLC

Study record dates

Study Major Dates

• Study Start (ACTUAL): September 11, 2019
• Primary Completion (ACTUAL): December 20, 2021
• Study Completion (ACTUAL): October 26, 2022

Study Registration Dates

• First Submitted: September 18, 2019
• First Submitted That Met QC Criteria: September 19, 2019
• First Posted (ACTUAL): September 23, 2019

Study Record Updates

• Last Update Posted (ACTUAL): February 8, 2023
• Last Update Submitted That Met QC Criteria: January 13, 2023
• Last Verified: December 1, 2022

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Digestive System Diseases; Neoplasms; Neoplasms by Site; Gastrointestinal Neoplasms; Digestive System Neoplasms; Gastrointestinal Diseases; Stomach Diseases; Stomach Neoplasms; Antineoplastic Agents; Antineoplastic Agents, Immunological; Pembrolizumab; Bavituximab
• Other Study ID Numbers: ONCG100; 2019-000949-13 (EUDRACT_NUMBER); KEYNOTE PN978 (OTHER: Merck)

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No